glp-1 and thyroid medication Implications of Receptor Agonist on Function: A Literature Review of Its Effects on Thyroid Volume, Risk of Cancer, Functionality TSH Levels Letter: Association Between Incretin Mimetics

Overall Adverse Event Rates Dose Group Any Adverse Event (%) GI Adverse Events (%) Discontinuation Due to AE (%) Placebo 72.1% 32.6% 0% 1 mg 88.6% 48.6% 2.9% 4 mg (escalated) 88.6% 60.0% 5.7% 4 mg (single dose) 90.9% 63.6% 6.1% 8 mg (escalated) 87.5% 57.5% 5.0% 8 mg (single dose) 88.6% 62.9% 5.7% 12 mg (escalated) 97.2% 66.7% 8.3% Source: Jastreboff AM, Kaplan LM, Fras JP, et al

Influence of CYP2C9 Polymorphisms, Demographic Factors and Concomitant Drug Therapy on Warfarin Metabolism and Maintenance Dose

doi: 10.3390/diabetology2020004 43 BornerTGeislerCEFortinSMCosgroveRAlsina-FernandezJDograMet al

HyperCharge is Hope

What are the clinical data for Semax in ischemic stroke

(and GO P53!!!)